Bristol Myers Squibb
Leading American pharmaceutical company specializing in research and development.
Operating headquarters
New York City, NY, USFounded
1887Leading American pharmaceutical company specializing in research and development.
Bristol Myers Squibb competes on the breadth of its marketed portfolio, with established franchises in oncology immunotherapy, oral immunology, and cardiovascular medicine. Flagship products such as Opdivo, Zeposia, Sotyktu, and Cobenfy give it commercial positions across cancer, multiple sclerosis, ulcerative colitis, psoriasis, and schizophrenia.
Its late-stage pipeline and acquired platforms add further differentiation, including the first CELMoD-based Zenbexus combination for multiple myeloma and an actinium-based radiopharmaceutical platform from RayzeBio. This combination of marketed breadth and modality diversification supports durability as individual products face competition.
Source: bms.com
The company enters the second half of 2026 with regulatory momentum from Hodgkin lymphoma expansions for Opdivo and the accelerated Zenbexus approval in relapsed multiple myeloma. Management scheduled third-quarter 2026 results for late October, framing near-term attention on commercial execution across the oncology and immunology portfolios.
Longer-term prospects rest on integrating the Mirati, RayzeBio, and Karuna acquisitions into marketed growth drivers. Success depends on converting the neuroscience and radiopharmaceutical platforms into approved products while sustaining share for mature immunotherapy and oral franchises.
Source: bms.com
Bristol Myers Squibb is a global biopharmaceutical company built around innovative medicines in oncology, immunology, cardiovascular disease, and neuroscience. Its commercial engine spans infused immunotherapies, once-daily oral agents, and newer mechanisms such as selective TYK2 inhibition and muscarinic agonism for schizophrenia.
Capital allocation emphasizes pipeline renewal through acquisition alongside internal development, as shown by the completed Karuna, RayzeBio, and Mirati deals. The investment case centers on whether these acquired platforms and recent approvals offset maturity in older franchises over the coming years.
Source: bms.com